MedTrace Logo

Translational Study of Molecular Classification of Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT05318391 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 324

Last updated 2022-04-08

No results posted yet for this study

Summary

The purpose of the study is to investigate the proportion of the cell-of-origin (COO) subtypes in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) treated with BTK inhibitor or lenalidomide and its biosimilars.

Conditions

  • Lymphoma, Large B-Cell, Diffuse
  • Gene Expression Profiling

Interventions

DIAGNOSTIC_TEST

Gene expression profile

Diagnostic Test: The Canhelp-COO Assay (Canhelp Genomics CO., Ltd) for differentiating COO subtypes using gene expression analysis by real-time PCR (RT-PCR)

Sponsors & Collaborators

  • Wuxi People's Hospital

    collaborator OTHER

  • Shanghai Minhang Central Hospital

    collaborator OTHER

  • Shanghai Zhongshan Hospital

    lead OTHER

Principal Investigators

  • Peng Liu, MD,PhD · Fudan University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-14
Primary Completion
2022-01-30
Completion
2022-03-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05318391 on ClinicalTrials.gov